Mechanism of drug resistance to dasatinib (BMS-354825) and imatinib in chronic myelogenous leukemia cells.

被引：0
|
作者：
Okabe, Seiichi
Tauchi, Tetsuzo
Broxmeyer, Hal E.
Ohyashiki, Kazuma
机构：
[1] Tokyo Med Univ, Dept Internal Med 1, Tokyo, Japan
[2] Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1386
引用
收藏
页码：404A / 404A
页数：1
相关论文
共 50 条
  • [1] Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML)
    Lee, FY
    Wen, ML
    Bhide, R
    Camuso, A
    Castenada, S
    Fager, K
    Flefleh, C
    Inigo, I
    Kan, D
    Luo, R
    Mcglinchey, K
    Smykla, R
    Wild, R
    Borzilleri, R
    Lombardo, L
    BLOOD, 2005, 106 (11) : 564A - 565A
  • [2] Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam, S
    Lee, F
    Jove, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9029S - 9029S
  • [3] Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib.
    Quintas-Cardama, A.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Jabbour, E.
    O'Brien, S.
    Luthra, R.
    Wierda, W.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [4] Dasatinib (BMS-354825) inhibits stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Nam, Sangkil
    Lee, Francis
    Jove, Richard
    CANCER RESEARCH, 2006, 66 (08)
  • [5] Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Nam, Sangkil
    Williams, Ann
    Vultur, Adina
    List, Alan
    Halla, Kapil
    Smith, David
    Lee, Francis Y.
    Jove, Richard
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1400 - 1405
  • [6] The SRC/ABL inhibitor BMS-354825 overcomes resistance to imatinib mesylate in chronic myelogenous leukemia cells through multiple mechanisms.
    Donato, NJ
    Wu, J
    Kong, LY
    Lee, F
    Talpaz, M
    BLOOD, 2004, 104 (11) : 549A - 549A
  • [7] Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN 107) therapy failure
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Jones, Dan
    Nicaise, Claude
    O'Brien, Susan
    Giles, Francis
    Talpaz, Moshe
    Cortes, Jorge
    BLOOD, 2007, 109 (02) : 497 - 499
  • [8] Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
    Fiskus, Warren
    Pranpat, Michael
    Balasis, Maria
    Bali, Purva
    Estrella, Veronica
    Kumaraswamy, Sandhya
    Rao, Rekha
    Rocha, Kathy
    Herger, Bryan
    Lee, Francis
    Richon, Victoria
    Bhalla, Kapil
    CLINICAL CANCER RESEARCH, 2006, 12 (19) : 5869 - 5878
  • [9] BMS-214662 targets quiescent chronic myeloid leukaemia stem cells and enhances the activity of both imatinib and dasatinib (BMS-354825).
    Copland, M
    Hamilton, A
    Allan, EK
    Brunton, V
    Holyoake, TL
    BLOOD, 2005, 106 (11) : 204A - 205A
  • [10] BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia
    Doggrell, SA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (01) : 89 - 91
12345